Lead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CDSCO Approves Wockhardt’s New Generation Oral Antibiotic Miqnaf
Details : Miqnaf (nafithromycin) is a novel antibiotic discovered and being developed for the treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults.
Product Name : Miqnaf
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 03, 2025
Lead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Indian Drug Regulator Recommends Wockhardt's Miqnaf for Treatment of CABP
Details : Miqnaf (nafithromycin) is a novel antibiotic discovered and being developed for the treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults.
Product Name : Miqnaf
Product Type : Small molecule
Upfront Cash : Not Applicable
October 14, 2024
Lead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Jiangxi Jemincare Group Company
Deal Size : Undisclosed
Deal Type : Partnership
Wockhardt and Jemincare Partner for Novel Respiratory Antibiotic Nafithromycin
Details : Under the terms of the definitive agreement, Jemincare will be responsible for exclusive development and commercialization of the Nafithromycin in the select markets.
Product Name : WCK 4873
Product Type : Small molecule
Upfront Cash : Undisclosed
August 26, 2021
Lead Product(s) : Nafithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Jiangxi Jemincare Group Company
Deal Size : Undisclosed
Deal Type : Partnership